Q-omics provides the consensus-scored CDK20 profile across patient tissues and cancer cell-line models. CDK20 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDK20 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CDK20 RNA expression shows 19,738 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where CDK20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK20 survival associations across molecular data types. CDK20 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK20 RNA expression–survival associations across cancer types. High CDK20 expression shows unfavorable associations in LUSC, ESCA, COAD and LIHC, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDK20 RNA expression.
This table summarizes CDK20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CDK20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK20 shows lower tumor expression in THCA, KICH, COAD and LUSC and higher tumor expression in BRCA and LIHC. The THCA box plot shows higher CDK20 RNA expression in normal versus tumor tissue (log2 FC = −0.666, t-test p < 0.001).
This table shows molecular features associated with CDK20 in patient tissues and cancer cell lines. In patient samples, CDK20 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
